Literature DB >> 25939664

Juvenile myelomonocytic leukemia due to a germline CBL Y371C mutation: 35-year follow-up of a large family.

Anand Pathak1, Alexander Pemov, Mary L McMaster, Ramita Dewan, Sarangan Ravichandran, Evgenia Pak, Amalia Dutra, Hyo Jung Lee, Aurelie Vogt, Xijun Zhang, Meredith Yeager, Stacie Anderson, Martha Kirby, Neil Caporaso, Mark H Greene, Lynn R Goldin, Douglas R Stewart.   

Abstract

Juvenile myelomonocytic leukemia (JMML) is a pediatric myeloproliferative neoplasm that arises from malignant transformation of the stem cell compartment and results in increased production of myeloid cells. Somatic and germline variants in CBL (Casitas B-lineage lymphoma proto-oncogene) have been associated with JMML. We report an incompletely penetrant CBL Y371C mutation discovered by whole-exome sequencing in three individuals with JMML in a large pedigree with 35 years of follow-up. The Y371 residue is highly evolutionarily conserved among CBL orthologs and paralogs. In silico bioinformatics prediction programs suggested that the Y371C mutation is highly deleterious. Protein structural modeling revealed that the Y371C mutation abrogated the ability of the CBL protein to adopt a conformation that is required for ubiquitination. Clinically, the three mutation-positive JMML individuals exhibited variable clinical courses; in two out of three, primary hematologic abnormalities persisted into adulthood with minimal clinical symptoms. The penetrance of the CBL Y371C mutation was 30% for JMML and 40% for all leukemia. Of the 8 mutation carriers in the family with available photographs, only one had significant dysmorphic features; we found no evidence of a clinical phenotype consistent with a "CBL syndrome". Although CBL Y371C has been previously reported in familial JMML, we are the first group to follow a complete pedigree harboring this mutation for an extended period, revealing additional information about this variant's penetrance, function and natural history.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25939664      PMCID: PMC6941732          DOI: 10.1007/s00439-015-1550-9

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  44 in total

1.  RING finger mutations that abolish c-Cbl-directed polyubiquitination and downregulation of the EGF receptor are insufficient for cell transformation.

Authors:  C B Thien; F Walker; W Y Langdon
Journal:  Mol Cell       Date:  2001-02       Impact factor: 17.970

2.  Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules.

Authors:  Yi Zhang; Alejandro Wolf-Yadlin; Phillip L Ross; Darryl J Pappin; John Rush; Douglas A Lauffenburger; Forest M White
Journal:  Mol Cell Proteomics       Date:  2005-06-11       Impact factor: 5.911

Review 3.  Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS)

Authors:  C M Niemeyer; M Arico; G Basso; A Biondi; A Cantu Rajnoldi; U Creutzig; O Haas; J Harbott; H Hasle; G Kerndrup; F Locatelli; G Mann; B Stollmann-Gibbels; E T van't Veer-Korthof; E van Wering; M Zimmermann
Journal:  Blood       Date:  1997-05-15       Impact factor: 22.113

4.  Autoinhibition and phosphorylation-induced activation mechanisms of human cancer and autoimmune disease-related E3 protein Cbl-b.

Authors:  Yoshihiro Kobashigawa; Akira Tomitaka; Hiroyuki Kumeta; Nobuo N Noda; Masaya Yamaguchi; Fuyuhiko Inagaki
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-07       Impact factor: 11.205

5.  Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.

Authors:  Marco Tartaglia; Charlotte M Niemeyer; Alessandra Fragale; Xiaoling Song; Jochen Buechner; Andreas Jung; Karel Hählen; Henrik Hasle; Jonathan D Licht; Bruce D Gelb
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

6.  Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.

Authors:  Masashi Sanada; Takahiro Suzuki; Lee-Yung Shih; Makoto Otsu; Motohiro Kato; Satoshi Yamazaki; Azusa Tamura; Hiroaki Honda; Mamiko Sakata-Yanagimoto; Keiki Kumano; Hideaki Oda; Tetsuya Yamagata; Junko Takita; Noriko Gotoh; Kumi Nakazaki; Norihiko Kawamata; Masafumi Onodera; Masaharu Nobuyoshi; Yasuhide Hayashi; Hiroshi Harada; Mineo Kurokawa; Shigeru Chiba; Hiraku Mori; Keiya Ozawa; Mitsuhiro Omine; Hisamaru Hirai; Hiromitsu Nakauchi; H Phillip Koeffler; Seishi Ogawa
Journal:  Nature       Date:  2009-07-20       Impact factor: 49.962

7.  Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras.

Authors:  R Kalra; D C Paderanga; K Olson; K M Shannon
Journal:  Blood       Date:  1994-11-15       Impact factor: 22.113

8.  dbNSFP v2.0: a database of human non-synonymous SNVs and their functional predictions and annotations.

Authors:  Xiaoming Liu; Xueqiu Jian; Eric Boerwinkle
Journal:  Hum Mutat       Date:  2013-07-10       Impact factor: 4.878

9.  Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden Markov models.

Authors:  Hashem A Shihab; Julian Gough; David N Cooper; Peter D Stenson; Gary L A Barker; Keith J Edwards; Ian N M Day; Tom R Gaunt
Journal:  Hum Mutat       Date:  2012-11-02       Impact factor: 4.878

10.  Dubowitz syndrome is a complex comprised of multiple, genetically distinct and phenotypically overlapping disorders.

Authors:  Douglas R Stewart; Alexander Pemov; Jennifer J Johnston; Julie C Sapp; Meredith Yeager; Ji He; Joseph F Boland; Laurie Burdett; Christina Brown; Richard A Gatti; Blanche P Alter; Leslie G Biesecker; Sharon A Savage
Journal:  PLoS One       Date:  2014-06-03       Impact factor: 3.240

View more
  9 in total

1.  Rare germline variants in known melanoma susceptibility genes in familial melanoma.

Authors:  Alisa M Goldstein; Yanzi Xiao; Joshua Sampson; Bin Zhu; Melissa Rotunno; Hunter Bennett; Yixuan Wen; Kristine Jones; Aurelie Vogt; Laurie Burdette; Wen Luo; Bin Zhu; Meredith Yeager; Belynda Hicks; Jiali Han; Immaculata De Vivo; Stella Koutros; Gabriella Andreotti; Laura Beane-Freeman; Mark Purdue; Neal D Freedman; Stephen J Chanock; Margaret A Tucker; Xiaohong R Yang
Journal:  Hum Mol Genet       Date:  2017-12-15       Impact factor: 6.150

2.  Integrated Analysis of Coexpression and Exome Sequencing to Prioritize Susceptibility Genes for Familial Cutaneous Melanoma.

Authors:  Sally Yepes; Margaret A Tucker; Hela Koka; Yanzi Xiao; Tongwu Zhang; Kristine Jones; Aurelie Vogt; Laurie Burdette; Wen Luo; Bin Zhu; Amy Hutchinson; Meredith Yeager; Belynda Hicks; Kevin M Brown; Neal D Freedman; Stephen J Chanock; Alisa M Goldstein; Xiaohong R Yang
Journal:  J Invest Dermatol       Date:  2022-02-16       Impact factor: 7.590

Review 3.  A Systematic Literature Review of Whole Exome and Genome Sequencing Population Studies of Genetic Susceptibility to Cancer.

Authors:  Alisa M Goldstein; Elizabeth M Gillanders; Melissa Rotunno; Rolando Barajas; Mindy Clyne; Elise Hoover; Naoko I Simonds; Tram Kim Lam; Leah E Mechanic
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-05-28       Impact factor: 4.254

4.  Unexpected Findings in a Child with Atypical Hemolytic Uremic Syndrome: An Example of How Genomics Is Changing the Clinical Diagnostic Paradigm.

Authors:  Eleanor G Seaby; Rodney D Gilbert; Gaia Andreoletti; Reuben J Pengelly; Catherine Mercer; David Hunt; Sarah Ennis
Journal:  Front Pediatr       Date:  2017-05-22       Impact factor: 3.418

5.  Research participant interest in primary, secondary, and incidental genomic findings.

Authors:  Jennifer T Loud; Renee C Bremer; Phuong L Mai; June A Peters; Neelam Giri; Douglas R Stewart; Mark H Greene; Blanche P Alter; Sharon A Savage
Journal:  Genet Med       Date:  2016-04-21       Impact factor: 8.822

Review 6.  Cracking the Monoubiquitin Code of Genetic Diseases.

Authors:  Raj Nayan Sewduth; Maria Francesca Baietti; Anna A Sablina
Journal:  Int J Mol Sci       Date:  2020-04-25       Impact factor: 5.923

7.  Somatic variation as an incidental finding in the pediatric next-generation sequencing era.

Authors:  Marilena Melas; Mariam T Mathew; Mari Mori; Vijayakumar Jayaraman; Sarah A Wilson; Cortlandt Martin; Amanda E Jacobson-Kelly; Ben J Kelly; Vincent Magrini; Elaine R Mardis; Catherine E Cottrell; Kristy Lee
Journal:  Cold Spring Harb Mol Case Stud       Date:  2021-12-09

Review 8.  Role of CBL Mutations in Cancer and Non-Malignant Phenotype.

Authors:  Davide Leardini; Daria Messelodi; Edoardo Muratore; Francesco Baccelli; Salvatore N Bertuccio; Laura Anselmi; Andrea Pession; Riccardo Masetti
Journal:  Cancers (Basel)       Date:  2022-02-08       Impact factor: 6.639

9.  VAV1-Cre mediated hematopoietic deletion of CBL and CBL-B leads to JMML-like aggressive early-neonatal myeloproliferative disease.

Authors:  Wei An; Bhopal C Mohapatra; Neha Zutshi; Timothy A Bielecki; Benjamin T Goez; Haitao Luan; Fany Iseka; Insha Mushtaq; Matthew D Storck; Vimla Band; Hamid Band
Journal:  Oncotarget       Date:  2016-09-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.